Yoffe Investment Management LLC Makes New Investment in Haleon plc (NYSE:HLN)

Yoffe Investment Management LLC bought a new position in Haleon plc (NYSE:HLN) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 17,073 shares of the company’s stock, valued at approximately $163,000.

Other institutional investors have also made changes to their positions in the company. Sierra Ocean LLC acquired a new position in Haleon during the fourth quarter valued at $26,000. Versant Capital Management Inc grew its stake in Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after acquiring an additional 3,348 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Haleon in the 4th quarter valued at about $35,000. Toronto Dominion Bank lifted its position in shares of Haleon by 3,470.0% in the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares in the last quarter. Finally, Spire Wealth Management acquired a new stake in shares of Haleon during the fourth quarter worth approximately $39,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on HLN shares. Hsbc Global Res downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. HSBC reiterated a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Finally, Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Six analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.95.

Haleon Trading Down 5.4 %

Haleon stock opened at $9.89 on Friday. Haleon plc has a one year low of $7.99 and a one year high of $10.80. The company’s fifty day moving average price is $10.03 and its two-hundred day moving average price is $9.87. The company has a market capitalization of $44.75 billion, a price-to-earnings ratio of 29.07, a PEG ratio of 2.82 and a beta of 0.25. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon (NYSE:HLN) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. On average, analysts forecast that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This is an increase from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. Haleon’s dividend payout ratio is currently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.